Business Description
BioLine Rx Ltd
ISIN : US09071M1062
Share Class Description:
STU:YP2A: ADRCompare
Compare
Traded in other countries / regions
BLRX.IsraelBLRX.USAYP2A.Germany IPO Date
2014-06-18Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.99 | |||||
| Equity-to-Asset | 0.16 | |||||
| Debt-to-Equity | 3.48 | |||||
| Debt-to-EBITDA | -2.22 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25 | |||||
| 3-Year FCF Growth Rate | 36.4 | |||||
| 3-Year Book Growth Rate | -42.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 72.77 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 13.99 | |||||
| 9-Day RSI | 22.9 | |||||
| 14-Day RSI | 28.2 | |||||
| 3-1 Month Momentum % | -24.4 | |||||
| 6-1 Month Momentum % | -31.9 | |||||
| 12-1 Month Momentum % | -73.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.52 | |||||
| Quick Ratio | 1.37 | |||||
| Cash Ratio | 1.17 | |||||
| Days Inventory | 142.18 | |||||
| Days Sales Outstanding | 41.41 | |||||
| Days Payable | 408.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -46 | |||||
| Shareholder Yield % | -31.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.78 | |||||
| Operating Margin % | -126.63 | |||||
| Net Margin % | -90.58 | |||||
| FCF Margin % | -138.06 | |||||
| ROE % | -160.88 | |||||
| ROA % | -34.86 | |||||
| ROIC % | -83.33 | |||||
| 3-Year ROIIC % | -345.28 | |||||
| ROC (Joel Greenblatt) % | -894.8 | |||||
| ROCE % | -52.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.97 | |||||
| PB Ratio | 2.72 | |||||
| EV-to-EBIT | -1.42 | |||||
| EV-to-Forward-EBIT | -2.6 | |||||
| EV-to-EBITDA | -1.74 | |||||
| EV-to-Forward-EBITDA | -2.6 | |||||
| EV-to-Revenue | 1.05 | |||||
| EV-to-Forward-Revenue | 5.27 | |||||
| EV-to-FCF | -0.84 | |||||
| Earnings Yield (Greenblatt) % | -70.25 | |||||
| FCF Yield % | -133.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioLine Rx Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 20.173 | ||
| EPS (TTM) (€) | -0.207 | ||
| Beta | -0.55 | ||
| 3-Year Sharpe Ratio | -0.46 | ||
| 3-Year Sortino Ratio | -0.64 | ||
| Volatility % | 78.1 | ||
| 14-Day RSI | 28.2 | ||
| 14-Day ATR (€) | 0.029013 | ||
| 20-Day SMA (€) | 0.28385 | ||
| 12-1 Month Momentum % | -73.25 | ||
| 52-Week Range (€) | 0.199 - 1.5 | ||
| Shares Outstanding (Mil) | 84.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioLine Rx Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(STU:YP2A)'s stock price today?
The current price of STU:YP2A is €0.20. The 52 week high of STU:YP2A is €1.50 and 52 week low is €0.20.
When is next earnings date of BioLine Rx Ltd(STU:YP2A)?
The next earnings date of BioLine Rx Ltd(STU:YP2A) is 2025-03-26 Est..
Does BioLine Rx Ltd(STU:YP2A) pay dividends? If so, how much?
BioLine Rx Ltd(STU:YP2A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers